Parkinsons-Disease-Information-Page

Parkinsons-Disease-Information-Page

Parkinson's Disease Information Page

What research is being done?

Current research programs funded by the National Institute of Neurological Disorders and Stroke (NINDS) are using animal models to study how the disease progresses and to develop new drug therapies. Scientists looking for the cause of PD continue to search for possible environmental factors, such as toxins, that may trigger the disorder, and study genetic factors to determine how defective genes play a role.  Researchers are investigating how cellular processes controlled by genes contribute to neurodegeneration (the breakdown and death of nerve cells), including the toxic accumulation of the protein alpha-synuclein in nerve cells and how the loss of dopamine impairs communication between nerve cells.  Other scientists are working to develop new protective drugs that can delay, prevent, or reverse the disease.  Key NINDS programs include the Parkinson's Disease Biomarkers Program, which is aimed at discovering biomarkers--new ways to identify people at risk for developing PD and to track the progression of the disease; and the Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD), in which the National Institutes of Health, multiple biopharmaceutical and life science communities, and nonprofit advocacy organizations work to identify and validate biomarkers for PD.  More information about Parkinson's Disease research is available at:
Focus on Parkinson's Disease Research

Information from the National Library of Medicine’s MedlinePlus
Parkinson's Disease

×
What research is being done?

Current research programs funded by the National Institute of Neurological Disorders and Stroke (NINDS) are using animal models to study how the disease progresses and to develop new drug therapies. Scientists looking for the cause of PD continue to search for possible environmental factors, such as toxins, that may trigger the disorder, and study genetic factors to determine how defective genes play a role.  Researchers are investigating how cellular processes controlled by genes contribute to neurodegeneration (the breakdown and death of nerve cells), including the toxic accumulation of the protein alpha-synuclein in nerve cells and how the loss of dopamine impairs communication between nerve cells.  Other scientists are working to develop new protective drugs that can delay, prevent, or reverse the disease.  Key NINDS programs include the Parkinson's Disease Biomarkers Program, which is aimed at discovering biomarkers--new ways to identify people at risk for developing PD and to track the progression of the disease; and the Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD), in which the National Institutes of Health, multiple biopharmaceutical and life science communities, and nonprofit advocacy organizations work to identify and validate biomarkers for PD.  More information about Parkinson's Disease research is available at:
Focus on Parkinson's Disease Research

Information from the National Library of Medicine’s MedlinePlus
Parkinson's Disease

Current research programs funded by the National Institute of Neurological Disorders and Stroke (NINDS) are using animal models to study how the disease progresses and to develop new drug therapies. Scientists looking for the cause of PD continue to search for possible environmental factors, such as toxins, that may trigger the disorder, and study genetic factors to determine how defective genes play a role.  Researchers are investigating how cellular processes controlled by genes contribute to neurodegeneration (the breakdown and death of nerve cells), including the toxic accumulation of the protein alpha-synuclein in nerve cells and how the loss of dopamine impairs communication between nerve cells.  Other scientists are working to develop new protective drugs that can delay, prevent, or reverse the disease.  Key NINDS programs include the Parkinson's Disease Biomarkers Program, which is aimed at discovering biomarkers--new ways to identify people at risk for developing PD and to track the progression of the disease; and the Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD), in which the National Institutes of Health, multiple biopharmaceutical and life science communities, and nonprofit advocacy organizations work to identify and validate biomarkers for PD.  More information about Parkinson's Disease research is available at:
Focus on Parkinson's Disease Research

Information from the National Library of Medicine’s MedlinePlus
Parkinson's Disease


Definition
Definition
Treatment
Treatment
Prognosis
Prognosis
Clinical Trials
Clinical Trials
Organizations
Organizations
Publications
Publications
135 Parkinson Avenue
Staten Island, NY 10305-1425
Tel: 718-981-8001; 800-223-2732; 877-223-3801 (Young Onset Center)
357 S. McCaslin Boulevard, Suite 105
Louisville, CO 80027
Tel: 866-358-0285; 303-733-3340
Grand Central Station
P.O. Box 4777
New York, NY 10163
Tel: 212-509-0995
P.O. Box 308
Kingston, NJ 08528-0308
Tel: 609-688-0870; 800-579-8440
1359 Broadway
Suite 1509
New York, NY 10018
Tel: 800-473-4636
74-090 El Paseo, Suite 104
Palm Desert, CA 92260
Tel: 760-773-5628; 877-775-4111; 877-775-4111
2500 Hospital Drive
Building #0, Suite 1
Mountain View, CA 94040
Tel: 408-734-2800; 800-655-2273